J
Jean-Jacques Tuech
Researcher at University of Rouen
Publications - 259
Citations - 7876
Jean-Jacques Tuech is an academic researcher from University of Rouen. The author has contributed to research in topics: Medicine & Endometriosis. The author has an hindex of 40, co-authored 233 publications receiving 6530 citations. Previous affiliations of Jean-Jacques Tuech include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Pauline Maby,Mihaela Angelova,David Tougeron,Sarah E. Church,Sarah E. Church,Sarah E. Church,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Maria Fischer,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Maristella Sasso,Maristella Sasso,Maristella Sasso,Amélie M. Bilocq,Amélie M. Bilocq,Amélie M. Bilocq,Amos Kirilovsky,Amos Kirilovsky,Amos Kirilovsky,Anna C. Obenauf,Mohamad Hamieh,Anne Berger,Patrick Bruneval,Jean-Jacques Tuech,Jean-Christophe Sabourin,Florence Le Pessot,Jacques Mauillon,Arash Rafii,Pierre Laurent-Puig,Pierre Laurent-Puig,Michael R. Speicher,Zlatko Trajanoski,Pierre Michel,Richard Sesboüé,Thierry Frebourg,Thierry Frebourg,Franck Pagès,Viia Valge-Archer,Viia Valge-Archer,Jean-Baptiste Latouche,Jérôme Galon,Jérôme Galon,Jérôme Galon +52 more
TL;DR: Assessment of the immune status via Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability staging that could be an important guide for immunotherapy strategies.
Journal ArticleDOI
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
F. Di Fiore,F. Blanchard,Françoise Charbonnier,F. Le Pessot,A. Lamy,M.P. Galais,L Bastit,Audrey Killian,Richard Sesboüé,Jean-Jacques Tuech,A.-M. Queuniet,Bernard Paillot,Jean-Christophe Sabourin,Francis Michot,Pierre Michel,Thierry Frebourg +15 more
TL;DR: It is confirmed that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
Journal ArticleDOI
Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).
Jérémie H. Lefevre,Laurent Mineur,Salma Kotti,Eric Rullier,Philippe Rouanet,Cécile de Chaisemartin,Bernard Meunier,Jafari Mehrdad,Eddy Cotte,Jérôme Desramé,Mehdi Karoui,Stéphane Benoist,Sylvain Kirzin,Anne Berger,Yves Panis,Guillaume Piessen,Alain Saudemont,Michel Prudhomme,Frédérique Peschaud,Anne Dubois,Jérôme Loriau,Jean-Jacques Tuech,Guillaume Meurette,Renato Lupinacci,Nicolas Goasgen,Yann Parc,Tabassome Simon,Emmanuel Tiret +27 more
TL;DR: Waiting 11 weeks after RCT did not increase the rate of pCR after surgical resection, and a longer waiting period may be associated with higher morbidity and more difficult surgical resections.
Journal ArticleDOI
Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial
Eric Rullier,Philippe Rouanet,Jean-Jacques Tuech,Alain Valverde,Bernard Lelong,Michel Rivoire,Jean-Luc Faucheron,Mehrdad Jafari,G. Portier,Bernard Meunier,Igor Sileznieff,Michel Prudhomme,Frédéric Marchal,Marc Pocard,Denis Pezet,Anne Rullier,Véronique Vendrely,Quentin Denost,Julien Asselineau,Adélaïde Doussau +19 more
TL;DR: A prospective, randomised, open-label, multicentre, phase 3 trial at 15 tertiary centres in France that were experts in the treatment of rectal cancer failed to show superiority of local excision over total mesorectal excision in patients with a good response after chemoradiotherapy.
Journal ArticleDOI
Guidelines for management of intra-abdominal infections
Philippe Montravers,Hervé Dupont,Marc Leone,Jean-Michel Constantin,Paul-Michel Mertes,Société française d'anesthésie et de réanimation,Pierre-François Laterre,Benoit Misset,Jean-Pierre Bru,Rémy Gauzit,Albert Sotto,Cécile Brigand,Antoine Hamy,Société française de chirurgie digestive,Jean-Jacques Tuech +14 more
TL;DR: The CPGs for peritonitis are based on a consensus between the various disciplines involved in the management of these patients concerning a number of themes such as: diagnostic strategy and the place of imaging; time to management; the Place of microbiological specimens; targets of empirical anti-infective therapy; duration of anti- Infective therapy.